Activities of Angel DZHAMBAZKI related to 2016/2057(INI)
Legal basis opinions (0)
Amendments (10)
Amendment 14 #
Draft opinion
Recital C
Recital C
C. whereas the WTO Doha Declaration on the TRIPS Agreement and Public Health acknowledges the role of intellectual property protection in the development of new medicines, while expressing concerns about its effects on prices, while especially keeping in mind drug development cycles;
Amendment 18 #
Draft opinion
Recital D
Recital D
D. whereas competition can lower costs, reduce expenditure on medicinesis an important factor in the overall balance of the pharmaceutical market and may positively affect and improved access to affordable medicines and foster more research and innovation;
Amendment 38 #
Draft opinion
Paragraph 2
Paragraph 2
Amendment 47 #
Draft opinion
Paragraph 2 b (new)
Paragraph 2 b (new)
2b. Considers that for a certain time period exclusive protection periods may be necessary in order to not disrupt the drug trial periods and thereby end the drug development cycle;
Amendment 48 #
Draft opinion
Paragraph 2 c (new)
Paragraph 2 c (new)
2c. Notes, that awareness and monitoring is an important aspect of the competent authorities and believes, that improved awareness campaigns are a tool to improve a better understanding of the complex drug development processes for both business and consumers;
Amendment 55 #
Draft opinion
Paragraph 3
Paragraph 3
3. Recalls that the Pharmaceutical Sector Inquiry Report adopted by the Commission in 2009 showed that some manufacturers of medicines have developed abusive strategies in connection with patent claims in order to hinder market entry of generic medicines, which should be avoided;
Amendment 57 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Notes that certain markets may benefit from more efficient monitoring and training for competent authorities as well as better inter-governmental cooperation in terms of exchange of best- practises;
Amendment 62 #
Draft opinion
Paragraph 4
Paragraph 4
4. Calls on the Commission to undertake a critical review of the impact of intellectual-property-related incentives on biomedical innovation, to explore alternatives to monopolies for the financing of medical R&D and to evaluate the functioning of the applicable limitations to patent allocationsassess areas where existing legislation may benefit from a modernisation or streamlining approach;
Amendment 68 #
Draft opinion
Paragraph 5
Paragraph 5
Amendment 80 #
Draft opinion
Paragraph 7
Paragraph 7